Global HER2 ADC Drugs for Cancer Market Research Report, Competitive, Technology and Forecast Analysis 2026-2033
Delivery：Within 72h| Full Report Selling Price |
|---|
2800.00 USD |
4200.00 USD |
5600.00 USD |
| Buy NowContact Us |
| Competitor Data Selling Price |
|---|
900.00 USD |
1350.00 USD |
1800.00 USD |
| Buy NowContact Us |
Market Overview
According to DIResearch＇s in-depth investigation and research, the global HER2 ADC Drugs for Cancer market size will reach 10,216 Million USD in 2026 and is projected to reach 17,836 Million USD by 2033, with a CAGR of 8.29% (2026-2033). Notably, the China HER2 ADC Drugs for Cancer market has changed rapidly in the past few years. By 2026, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
HER2 ADC drugs for cancer are a class of antibody–drug conjugates that target human epidermal growth factor receptor 2 and are used for the precise treatment of various HER2-positive tumors. These drugs employ highly specific monoclonal antibodies to recognize and bind to HER2, which is overexpressed on the surface of cancer cells, delivering potent cytotoxic payloads directly into tumor cells. This targeted approach enhances antitumor efficacy while minimizing damage to normal tissues. HER2 plays a critical role in multiple malignancies, including breast cancer, gastric cancer, and lung cancer, making it a well-established and clinically validated therapeutic target. Compared with conventional chemotherapy and single-agent targeted therapies, HER2 ADC drugs offer stronger targeting capability, improved therapeutic outcomes, and better safety profiles. With continuous advancements in conjugation technologies and payload optimization, HER2 ADC drugs show significant potential in prolonging patient survival and improving quality of life, and have become an important component of precision oncology.
The major global manufacturers of HER2 ADC Drugs for Cancer include Roche, AstraZeneca, Daiichi Sankyo, Remegen, Jiangsu Hengrui Medicine, Shanghai Henlius Biotech, Sichuan Kelun-Biotech Biopharmaceutical, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of HER2 ADC Drugs for Cancer. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global HER2 ADC Drugs for Cancer market. The report data covers historical data from 2021 to 2025, based year in 2026 and forecast data from 2027 to 2033.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the HER2 ADC Drugs for Cancer market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of HER2 ADC Drugs for Cancer industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of HER2 ADC Drugs for Cancer Include:
Roche
AstraZeneca
Daiichi Sankyo
Remegen
Jiangsu Hengrui Medicine
Shanghai Henlius Biotech
Sichuan Kelun-Biotech Biopharmaceutical
HER2 ADC Drugs for Cancer Product Segment Include:
Trastuzumab Type
Non-trastuzumab Type
HER2 ADC Drugs for Cancer Product Application Include:
Breast Cancer
Others
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global HER2 ADC Drugs for Cancer Industry PESTEL Analysis
Chapter 3: Global HER2 ADC Drugs for Cancer Industry Porter's Five Forces Analysis
Chapter 4: Global HER2 ADC Drugs for Cancer Major Regional Market Size (Sales, Revenue, Price) and Forecast Analysis
Chapter 5: Global HER2 ADC Drugs for Cancer Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)
Chapter 6: Global HER2 ADC Drugs for Cancer Sales, Revenue, Price and Forecast by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)
Chapter 8: Industrial Chain Analysis, HER2 ADC Drugs for Cancer Different Application Market Analysis (Sales and Revenue), Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Global HER2 ADC Drugs for Cancer Revenue, Sales and Market Share by Player
| Revenue (US$ Million) | 2020 | 2021 | 2022 | 2023 | 2024 |
| Roche | XX | XX | XX | XX | XX |
| AstraZeneca | XX | XX | XX | XX | XX |
| Daiichi Sankyo | XX | XX | XX | XX | XX |
| Remegen | XX | XX | XX | XX | XX |
| Jiangsu Hengrui Medicine | XX | XX | XX | XX | XX |
| Shanghai Henlius Biotech | XX | XX | XX | XX | XX |
| Sichuan Kelun-Biotech Biopharmaceutical | XX | XX | XX | XX | XX |
| Other Companies | XX | XX | XX | XX | XX |
| Total | XX | XX | XX | XX | XX |
| Sales (K Units) | 2020 | 2021 | 2022 | 2023 | 2024 |
| Roche | XX | XX | XX | XX | XX |
| AstraZeneca | XX | XX | XX | XX | XX |
| Daiichi Sankyo | XX | XX | XX | XX | XX |
| Remegen | XX | XX | XX | XX | XX |
| Jiangsu Hengrui Medicine | XX | XX | XX | XX | XX |
| Shanghai Henlius Biotech | XX | XX | XX | XX | XX |
| Sichuan Kelun-Biotech Biopharmaceutical | XX | XX | XX | XX | XX |
| Other Companies | XX | XX | XX | XX | XX |
| Total | XX | XX | XX | XX | XX |
Related Report
Global Dydrogesterone Drug Competitive Landscape Professional Research Report 2026
Global Dydrogesterone Drug Market Research Report, Competitive, Technology and Forecast Analysis 2026-2033
Global Olanzapine Competitive Landscape Professional Research Report 2026
Global Olanzapine Market Research Report, Competitive, Technology and Forecast Analysis 2026-2033
Global Oligonucleotide Pool Library Competitive Landscape Professional Research Report 2026
Global Oligonucleotide Pool Library Market Research Report, Competitive, Technology and Forecast Analysis 2026-2033
Global Oligonucleotide Therapeutics Competitive Landscape Professional Research Report 2026
Global Oligonucleotide Therapeutics Market Research Report, Competitive, Technology and Forecast Analysis 2026-2033
Order Process
Contact
1. Fill in your contact information, and the company will quickly match the specialist to get in touch with you
2. You can also directly call our customer service hotline or add customer service WeChat
Samples
1. One on one business specialist will send the complete version of the sample
2. If you need to customize the report, professional analysts will be arranged to communicate with you one-on-one and provide you with customized samples
Payment
1. Both parties sign a report purchase contract
2. Support Paypal, Visa, UnionPay and MasterCard Payment
Delivery
1. PDF report (sent online 2-3 working days after payment)
2. WORD version report (sent online 2-3 working days after payment)
3. Paper version report (sent via EMS or DHL within 3-5 working days after payment)
After-Sales
Within six months of purchasing the report, if you have any questions about the details of our report, you can contact the report analyst at any time. The analyst will continue to follow up and solve your problem until you are satisfied
